A First Time in Human Study Exploring Preliminary Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2017
At a glance
- Drugs GSK 2618960 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Biomarker; First in man; Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 01 Aug 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 07 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.